GlassScriptPhysician profile
Jason Hew
NPI 1083904197
$1,621.04
in general payments reported to CMS, 2019-2025
18 companies · $385 in 2025
The $385 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.17 · 2020: $64.03 · 2021: $459 · 2022: $248 · 2023: $316 · 2024: $75.49 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $719 · Education: $57.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $718.53 |
| Education | $57.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $314.56 | 2021-2025 | Tagrisso, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $248.90 | 2020-2024 | Eliquis |
| Amgen INC. | $173.10 | 2023-2025 | Imdelltra (Amg757), Kyprolis |
| Janssen Biotech, INC. | $168.51 | 2023-2025 | Darzalex, Talvey, Rybrevant |
| Puma Biotechnology, INC. | $116.26 | 2021 | |
| Pharmacosmos Therapeutics INC. | $114.09 | 2021 | |
| Incyte Corporation | $99.95 | 2022 | |
| Merck Sharp & Dohme LLC | $99.30 | 2023 | Keytruda |
| Eisai INC. | $51.76 | 2023-2024 | |
| Pfizer INC. | $46.86 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $39.91 | 2022 | |
| Exelixis INC. | $38.44 | 2019 | |
| Genentech USA, INC. | $23.79 | 2023 | Gazyva, Polivy, Venclexta |
| Gilead Sciences, INC. | $23.26 | 2019 | |
| Genzyme Corporation | $20.39 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caris Mpi, INC. | $16.17 | 2025 | Mi Cancer Seek |
| Glaxosmithkline, LLC. | $14.32 | 2020 | |
| Dova Pharmaceuticals | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Hew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.